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Abstract
Objective: To investigate if the survival of children with congenital anomalies
has improved from 2000 to 2015 and whether there is heterogeneity in the
improvements across Europe.
Design: Population-based study of routine collected data from the WHO data-
base on mortality and causes.
Setting: Data on 31 European countries from 2000 to 2015.
Main outcome measures: All-cause and congenital anomaly mortality rates
for infants and children up to age 9 in countries and regions of Europe.
Results: The relative odds of all-cause mortality in 2015 compared with 2000
was 0.54 (95% CI: 0.50–0.59) for under 1, 0.48 (95% CI: 0.44–0.53) for ages 1–4,
and 0.53 (95% CI: 0.49–0.56) for ages 5–9 with the relative odds of mortality
from congenital anomalies being 0.49 (95% CI: 0.44–0.55), 0.51 (95% CI:
0.44–0.60), and 0.65 (95% CI: 0.53–0.80), respectively. The proportion of deaths
from congenital anomalies remained relatively constant over time (26, 16, and
9% for under 1, ages 1–4, and ages 5–9, respectively) and was similar in all
regions of Europe. For mortality from all causes and from congenital anoma-
lies heterogeneity between countries and regions of Europe was high, with the
countries in Eastern Europe having higher rates, but also experiencing greater
relative reductions in mortality from 2000 to 2015.
Conclusion: There was a large geo-spatial disparity in all cause and congenital
anomaly mortality for infants and children up to 9. However, all regions saw a sig-
nificant decrease in all cause and congenital anomaly mortality rates, with the pro-
portions of deaths from congenital anomalies remaining constant over this time.
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1 | INTRODUCTION
Congenital anomalies are defined by the World Health
Organisation (WHO) as structural or functional abnor-
malities that occur prenatally and may be diagnosed
prenatally or in early infancy (WHO, 2020b). They lead
to high levels of disability and mortality (WHO, 2020b).
The 2010 Global Burden of Disease study found congeni-
tal anomalies accounted for 6% of infant deaths and 2.5%
of deaths in children aged 1–4 years globally (Lozano
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et al., 2012). Studies have suggested around 19.3% of neo-
natal deaths and 20.6% of infant deaths are due to con-
genital anomalies in more developed countries (Almli
et al., 2020; Roncancio et al., 2018).
Mortality from any cause and particularly from congen-
ital anomalies is much greater during infancy than child-
hood with over 80% of deaths in children under-5 actually
occurring in infants under 1 (Zylbersztejn, Gilbert, Hjern,
Wijlaars, & Hardelid, 2018). However, deaths in childhood,
particularly among children with congenital anomalies, do
occur and it is therefore important to monitor changes in
mortality in children as well as infants. Recent studies
(Göpfert, Sethi, Rakovac, & Mitis, 2015; Lyons &
Brophy, 2005; Onambele et al., 2019) have shown that all-
cause infant mortality has significantly decreased in
Europe, with an annual percentage change of −3.8%; from
8.3 to 3.6 per 1,000 live births from 1994 to 2015
(Onambele et al., 2019). However, in Europe there is lim-
ited recent research in mortality of children post infancy.
Lyons and Brophy (2005) showed a decrease in childhood
mortality by 50% from 1969 to 1992. Of concern is that
increased heterogeneity in mortality across Europe has
been reported with, for example, all-cause mortality being
lower in Scandinavian countries compared to Eastern
Europe countries (Lyons & Brophy, 2005). Child injury
deaths have been increasing in low-to-middle income
countries (LMIC) compared with high income countries
(HIC) by 31% (Göpfert et al., 2015).
Research has shown that the survival of infants with
congenital anomalies has improved in recent years
(Glinianaia et al., 2020; Schneuer et al., 2019; Tennant,
Pearce, Bythell, & Rankin, 2010; Wang, Hu, Druschel, &
Kirby, 2011). However, other studies have found no
significant change in survival (Dastgiri, Gilmour, &
Stone, 2003; Roncancio et al., 2018). Furthermore, some
research has suggested that the proportion of congenital
anomaly compared with all deaths increased slightly
from 1976 to 1985 across the USA and UK but not in
Sweden (Powell-Griner & Woolbright, 1990).
Therefore, this study used the WHO mortality data-
base (WHO, 2020a) to examine if mortality from congeni-
tal anomalies and all-cause childhood mortality has
continued to decrease in Europe from 2000 to 2015 and if
the relative contribution of deaths from congenital anom-
alies to total mortality in childhood has changed signifi-
cantly across Europe.
2 | METHODS
We extracted data for 31 European countries for years
2000–2015 from the WHO database on cause of death
(https://apps.who.int/healthinfo/statistics/mortality/cause
ofdeath_query/start.php). We used Detailed ICD-10 for
deaths data, selected Cause-group as all causes and “17
Congenital malformations, deformations and chromo-
somal abnormalities” for the age categories <1, 1, 2, 3, 4,
and 5–9 years. Where ICD 10 was not available, we used
detailed ICD-9 with for all causes and “14 Congenital
anomalies.” For the Ukraine we used 101-ICD-10 Mortal-
ity Tabulation List 1 with all-causes and “1093 Congenital
malformations, deformations, and chromosomal abnor-
malities”. For Portugal 2004 and 2005 data, we used
“UE1–ICD-10 special list for Portugal (data for
2004-2005)” and “CH00 ALL CAUSES OF DEATH” and
“CH17 CONGENITAL MALFORMATIONS, DEFORMA-
TIONS AND CHROMOSOMAL ABNORMALITIES.” For
Ireland pre 2006 we used “09A/09B–ICD9th revision,
(Standard) Basic Tabulation List” with “B00 All causes”
and “B44 Congenital anomalies” as causes. This gave us
almost a complete set of data for all 31 countries from
2000 to 2015. We did not impute any deaths data not
given. For population data we used the WHO database on
population and selected the 31 countries for the years
2000–2015 where available and then selected <1, 1, 2,
3, 4, 5–9 years of age categories. Where 2014/2015 popula-
tion data were not available, we used the previous year's
population data (Finland, Switzerland, and Ireland).
To allow us to look for disparities across Europe we
split the countries into four regions; Northern (Denmark,
Finland, Ireland, Norway, and Sweden, UK), Eastern
(Bulgaria, Croatia, Czech Republic, Estonia, Hungry, Lat-
via, Lithuania, Poland, Romania, Slovakia, Slovenia, and
Ukraine), Southern (Greece, Italy, Portugal, Spain,
Cyprus, and Malta), and Western (Austria, Belgium,
France, Germany, Luxemburg, Netherlands, and Switzer-
land) based on the geographic location within Europe
and as used by other studies (Bosetti et al., 2010;
Onambele et al., 2019).
2.1 | Statistical analysis methods
Mortality was analyzed separately for infants, for chil-
dren aged 1–4, and for children aged 5–9.
To examine trends in all-cause mortality over time we
fitted multilevel negative binomial regression models
with European region as the first level and within that
country as a random effect and each two-year period was
fitted independently as a fixed effect within country. This
takes into account the correlations within a country. Neg-
ative binomial regression models were used instead of
poisson regression models to allow for overdispersion.
Robust variance estimators were used. For each region,
the average marginal effects were calculated to estimate
the overall all-cause mortality in each region for each
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2-year period. Two-year periods were analyzed to be con-
sistent with other analyses in the paper for deaths from
congenital anomalies where displaying data by individual
year results in a lack of clarity due to small numbers hav-
ing wide sampling errors.
To illustrate the heterogeneity in trends over time
between countries within regions negative binomial
regression models were fitted within each country with
year as a continuous variable (rather than as a categorical
variable). A random-effects meta-analysis of the esti-
mated percentage change in mortality rate from 2000 to
2015 by country within region was performed and the
forest plot presented.
Similar models were fitted to analyze the trends in
mortality from congenital anomalies over time.
Multilevel logistic regression models were used to
investigate any changes over time in the relative propor-
tion of deaths due to congenital anomalies in the differ-
ent countries. European region was the first level and
within that country as a random effect and each year was
fitted independently as a fixed effect within country.
All analyses were performed in Stata version
15 (StatCorp, College Station, Texas).
3 | RESULTS
Table 1 shows for each country the average population
size and the numbers of deaths from all causes and con-
genital anomalies across the three age categories. The
countries differed in size with France having the biggest
average population with over 765,000 infants under 1 year
and Malta the smallest, with around 4,000 infants under
1 year.
3.1 | All-cause mortality
Figure 1 shows that infant all-cause mortality varied by
region; countries in Eastern Europe had almost twice the
mortality rate than those in the rest of Europe. Mortality
decreased in all countries (except for Malta) with an average
reduction of 46% (95% CI: 41–50%) (Table 2). On average
Eastern Europe saw the greatest decrease of 56% (95% CI:
48–62%), and Western the smallest decrease of 31% (95%
CI: 26–36%). Within each region of Europe there was con-
siderable heterogeneity, with all regions having an I2 over
88%, and there was also considerable heterogeneity between
the regions in Europe (I2 = 98.3%).
A similar pattern is seen for all-cause mortality in
children over 1 year of age, where countries in Eastern
Europe had almost twice the mortality of those in North-
ern Europe (Figure 1). In ages 1–4 mortality significantly
reduced by an average of 52% (95% CI: 47–56%) with all
countries apart from Greece seeing a significant reduc-
tion. Heterogeneity between countries and between
regions was slightly lower with a range from 66.9% I2
score in Northern Europe to 94.1% in Southern Europe
and an overall I2 score of 92.4%. In ages 5–9, Countries
from Eastern Europe had much higher mortality rates,
while countries from Southern Europe also had higher
mortality rates than those in Western and Northern
Europe but there was a similar overall reduction of 47%
(95% CI: 44–51%) with all countries seeing a reduction.
Heterogeneity remained relatively high but decreased
slightly with an I-squared score of 76.7% between
regions.
Overall, there was a significant decrease in mortality in
almost all countries across all ages up to 9 years while the
countries in Eastern Europe had the greatest decreases.
3.2 | Congenital anomaly mortality
Figure 2 shows that infant deaths from congenital anom-
alies varied by region of Europe, in particular Eastern
Europe had higher mortality than the rest of Europe.
However, infant mortality from congenital anomalies
decreased in all countries (except for Malta) with an aver-
age reduction of 51% (95% CI: 45–56%) (Table 2 and
Figure 3) across the 16 years. On average Eastern Europe
saw the greatest decrease of 58% (95% CI: 52–63%), and
Western Europe the smallest decrease of 32% (95% CI:
20–43%). Within each region of Europe there was consid-
erable heterogeneity, with all regions having an I2 over
85%, and there was also considerable heterogeneity
between the regions in Europe (I2 = 95.3%).
A similar pattern is seen for mortality from congen-
ital anomalies in children aged 1–4, where Eastern
Europe had the highest rates and all countries (apart
from Malta and Luxembourg) saw a reduction, varying
from 56% (95% CI: 40–68%) in Southern Europe to 34%
(95% CI: 23–43%) in Western Europe but with an aver-
age overall reduction of 49% (95% CI: 40–56%). Hetero-
geneity within regions decreased as well as between
the regions (I2 = 81.5%). In addition, Eastern Europe
still had much higher mortality rates for ages 5–9 and
there was an overall significant reduction of 35% (95%
CI: 20–47%) across Europe. However, most individual
countries did not see a statistically significant reduc-
tion. Heterogeneity between regions decreased
(I2 = 67.95) as well as heterogeneity within some
regions, which was as low as 17.2 and 23.6% in Western
and Northern Europe, respectively.
Overall there was a significant decrease in mortality
from congenital anomalies in Europe across all age






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 PITT AND MORRIS
groups up to nine with greater decreases at younger ages.
However, the decreases were not statistically significant
in all individual countries. Heterogeneity was high but
decreased as age increased.
3.3 | Congenital anomaly mortality
compared with all-cause mortality
The proportion of all deaths due to congenital anoma-
lies did not vary from 2000 to 2015 (data not shown).
Table 1 shows congenital anomaly deaths as a propor-
tion of all deaths for children up to age nine across four
regions of Europe for the whole time period. As age




















































































































































































































































































































































































































































































































FIGURE 1 All-cause mortality in four regions of Europe (95%
CI): 2000–2015 for ages under 1 year, 1–4 years, and 5–9 years





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 PITT AND MORRIS
anomalies decreased. On average Southern Europe had the
highest proportion of deaths due to congenital anomalies in
infants, and Western the lowest. However, there was a large
amount of variation between countries. Ireland, Greece,
and Malta had the highest proportions of infants
(37.9–40.8%), with Greece the highest for ages 1–4 as well.
For ages 5–9 Malta, Austria and Greece had the highest
proportions (18.5, 15.6, 15.3%, respectively). The countries
with the smallest proportions of deaths include Luxem-
bourg (15.4%), Cyprus (16.5%), and Bulgaria (19.9%) for
infants, Luxembourg (10%), France (10.3%), and Belgium
(11.2%) for ages 1–4 and Cyprus (2.8%), Romania (4.3%)
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FIGURE 2 Congenital anomaly mortality in four regions of
Europe (95%CI): 2000–2015 for ages under 1 year, 1–4 years, and
5–9 years
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4 | DISCUSSION
This study shows that from 2000 to 2015 in Europe there
was a decrease in all-cause mortality in infants and children
up to age 9 by an average of 46% (95% CI: 41–50%), 52%
(95% CI: 47–56%), and 47% (95% CI: 44–51%) for under
1, age 1–4 and age 5–9, respectively. Furthermore, deaths
from congenital anomalies also significantly decreased by
similar amounts; an average of 51% (95% CI: 45–56%), 49%
(95% CI: 40–56%), and 35% (95% CI: 20–47%) for under
1, age 1–4 and age 5–9, respectively. The proportion of
deaths due to a congenital anomaly, therefore, remained
relatively constant over the time period at around 28% of
infant deaths due to congenital anomalies, 17% of deaths
ages 1–4 and 10% of deaths for children aged 5–9. However,
there was significant heterogeneity in mortality rates across
Europe, where countries from Eastern Europe had the
highest mortality rates, but also experienced the greatest
both absolute and proportional reductions in mortality.
Our findings of a 46% (95% CI: 41–50%) decrease in
infant mortality over 16 years (2000–2015) is in line with
Onambele et al. (2019) findings of a − 3.8% annual change
in infant mortality in the EU from 1994 to 2015, using data
from the Eurostat database, furthermore supported by their
findings of higher mortality rates in Eastern Europe and
lower in Scandinavian countries (Onambele et al., 2019).
There are many possible reasons for the decline in all-
cause mortality, many linked to increases in socio-economic
status (Sartorius & Sartorius, 2014) as it can be seen that
where income is lower, infant health is lower and mortality
is higher (Spencer, 2004). A measure of income can be dis-
posable income; Northern and Western Europe had more
disposable income in 2016 compared with Eastern and
Southern Europe (Eurostat, 2018) helping to explain the het-
erogeneity in mortality seen. Furthermore, there was great
economic growth in the majority of Europe from 2003 to
2015 (Darvas, Mazza, & Midoes, 2019) which could partly
explain the decrease in mortality rate. However, Greece suf-
fered an economic crisis which caused them to decrease
their public health spending to less than any other pre-2004
EU member (Kentikelenis, Karanikolos, Reeves, McKee, &
Stuckler, 2014), which many have contributed to increasing
mortality and might explain their insignificant decrease in
death rate for age 1–4. Another factor in reducing infant and
childhood mortality is vaccines where a complete set of vac-
cines can reduce relative risk of mortality by 27% in children
(McGovern & Canning, 2015). This combined with Eastern
Europe having lower vaccination rates with the lowest vac-
cine coverage rate in Europe of 89.1% for infant DTP in
Romania compared with Northern Europe where Finland
and Sweden had the highest rate of 98.2% (Sheikh
et al., 2018) would explain the heterogeneity in mortality.
It has been shown that a lower perinatal mortality
rate in children with congenital anomalies is associated
with higher levels of TOPFA (termination of pregnancy
for fetal anomalies) (Best et al., 2020). This may explain
FIGURE 3 Relative odds of congenital anomaly death in 2015 compared with 2000 (95% CI) for ages under 1 year, 1–4 years, and
5–9 years
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the much higher percentages of deaths from congenital
anomalies, over 40% for infants, in Ireland and Malta
compared with other countries as TOPFA was illegal in
these countries, whereas in all the other countries such
terminations do occur (Boyle et al., 2018).
Almli et al. (2020) found a 10% decrease in infant deaths
from congenital anomalies from 2003 to 2017 in the United
States (Almli et al., 2020), compared with our observed
decrease in Europe of 51% over a similar time frame. How-
ever, there is considerable heterogeneity between countries,
with 10% not incomparable to some European countries. In
earlier studies Powell-Griner(1990) found the infant mortal-
ity rate from congenital anomalies declined by 30% in the
United States, 19% in Sweden, 37% in Scotland, and 34% in
England and Wales from the years 1976 to 1985 (Powell-
Griner & Woolbright, 1990). However, Dastgiri et al. (2003)
found no significant difference in survival rates of those
born with congenital anomalies over a slightly later time
period from 1980 to 1997 (Dastgiri et al., 2003) in Glasgow,
UK. Tennant et al. (2010) observed an annual 8% decrease
in mortality from 1985 to 2003 in Northern England. How-
ever, once the occurrence of terminations for fetal anoma-
lies was adjusted for, the decrease was reduced to 5% per
annum. These decreases are of a similar magnitude to those
observed here over a later time period.
Part of these decreases may be explained by the
increasing prevalence of prenatal screening and the sub-
sequent termination of pregnancies for fetal anomalies
(Liu et al., 2002; Loane et al., 2013; Richmond &
Atkins, 2005; Wyldes & Tonks, 2007) with many of those
terminations occurring in fetuses with lethal anomalies.
However, the birth prevalence of congenital anomalies
has remained relatively stable (Loane et al., 2013;
Taruscio et al., 2014) and in addition reductions in mor-
tality have also been seen in countries in which termina-
tions for fetal anomalies are illegal, such as Malta and
Ireland. This suggests that TOPFA is not the only reason
for the reduction in deaths from congenital anomalies.
The strength of this study is that the analysis is based
upon a very large data set from WHO covering a large
geographical region, derived from official death notifica-
tions. By comparing the WHO data set to EUROCAT data
for similar regions, Boyle did find all-cause and congeni-
tal deaths of infant to be reasonably complete (Boyle
et al., 2018) but there were countries (e.g., Finland)
where data for congenital anomaly deaths from
European Congenital Anomaly registries was 29% higher
than the WHO estimates (Boyle et al., 2018). This is likely
to occur when congenital anomalies had not been given
as the primary cause of death on death certificates.
The weakness of this study is as mentioned above
where the presence of a congenital anomaly could have
contributed to the death but if they were not the
underlying cause then the death would not have been
counted as a congenital anomaly death. In addition, the
data analyses all congenital anomalies and differences
may occur over time in the classification and recording of
minor anomalies. All the data analyzed is secondary data
so data collection methods are unknown as well is their
accuracy and there is a small amount of missing data for
some countries. As the number of live births and still-
births from congenital anomalies was not known, a full
analysis of survival from congenital anomalies could not
be completed and the effect of terminations could not be
evaluated. It would have been informative to have been
able to examine the mortality for specific congenital
anomalies, as the anomalies are extremely heteroge-
neous. However, such data were not available.
This study has used routine data to demonstrate that
the mortality from congenital anomalies decreased across
Europe from 2000 to 2015 and that differences between
countries (particularly those in Eastern Europe)
decreased. The improvements in survival in children with
congenital anomalies were very similar to those observed
in all children, resulting in the proportions of deaths due
to congenital anomalies to remain relatively constant.
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